REGN250110C770000
- 0.90
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Weekly Buzz: Last Short Week of Jan Sees Records, Trump Gives Orders
Wall Street Today: Market Pulls Back After Wild Week
Live Stock: First Week Down, Market Pulls Back a Hair After Records
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?
Wall Street Today: S&P 500 Closes at Record, Trump Keeps Appearing on TV
Express News | America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
Live Stock News: Market Waiting to See if the President Says Something Exciting Today
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,059
RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)
Wall Street Today: Does Anyone Have the Cash for Stargates
Live Stock: Stargate Rivals the Scale of the Manhattan Project, Musk Said it's a Pipe Dream
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating
Trump Rolls Back Effort to Lower Medicare, Medicaid Drug Costs
Wall Street Today: AI Domestic Investment News on the Way
Live Stock News: Market Climbs, Crypto Falls, Big Tech is Here and Trump Starts Signing Orders
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'This Company Has Never Lost Its Ability To Develop New Medicines'
Weekly Buzz: Finally a Good Week for 2025